EA200801520A1 - Химерные и гуманизированные антитела против человеческого интерлейкина-13 (il-13) - Google Patents

Химерные и гуманизированные антитела против человеческого интерлейкина-13 (il-13)

Info

Publication number
EA200801520A1
EA200801520A1 EA200801520A EA200801520A EA200801520A1 EA 200801520 A1 EA200801520 A1 EA 200801520A1 EA 200801520 A EA200801520 A EA 200801520A EA 200801520 A EA200801520 A EA 200801520A EA 200801520 A1 EA200801520 A1 EA 200801520A1
Authority
EA
Eurasian Patent Office
Prior art keywords
human interleukin
chemical
antibodies against
humanized antibodies
against human
Prior art date
Application number
EA200801520A
Other languages
English (en)
Russian (ru)
Inventor
Клэр Эшман
Мартин Джон Кэссиди
Джейн Элизабет Кларксон
Джонатан Генри Эллис
Тревор Энтони Кеннет Уоттэм
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35997844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200801520(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA200801520A1 publication Critical patent/EA200801520A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA200801520A 2006-01-11 2007-01-10 Химерные и гуманизированные антитела против человеческого интерлейкина-13 (il-13) EA200801520A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0600488.1A GB0600488D0 (en) 2006-01-11 2006-01-11 Immunoglobulins
PCT/EP2007/050219 WO2007080174A2 (en) 2006-01-11 2007-01-10 Chimeric and humanised anti-human il-13 antibodies

Publications (1)

Publication Number Publication Date
EA200801520A1 true EA200801520A1 (ru) 2009-02-27

Family

ID=35997844

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801520A EA200801520A1 (ru) 2006-01-11 2007-01-10 Химерные и гуманизированные антитела против человеческого интерлейкина-13 (il-13)

Country Status (18)

Country Link
EP (1) EP1976881A2 (enExample)
JP (1) JP2009523154A (enExample)
KR (1) KR20080113201A (enExample)
CN (1) CN101370829A (enExample)
AR (1) AR058955A1 (enExample)
AU (1) AU2007204372A1 (enExample)
BR (1) BRPI0706481A2 (enExample)
CA (1) CA2635972A1 (enExample)
CR (1) CR10161A (enExample)
EA (1) EA200801520A1 (enExample)
GB (1) GB0600488D0 (enExample)
IL (1) IL192207A0 (enExample)
MA (1) MA30156B1 (enExample)
NO (1) NO20082767L (enExample)
PE (1) PE20081185A1 (enExample)
TW (1) TW200736274A (enExample)
WO (1) WO2007080174A2 (enExample)
ZA (1) ZA200805526B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
MX2008014842A (es) 2006-05-25 2009-02-17 Glaxo Group Ltd Anticuerpos humanizados contra interleuquina-18 modificados.
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CA2744588A1 (en) * 2008-11-26 2010-06-03 Glaxo Group Limited Ligands that bind il-13
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
PE20120401A1 (es) * 2009-05-28 2012-05-04 Glaxo Group Ltd Proteina de enlace de il-13
NZ599100A (en) 2009-10-20 2014-07-25 Abbvie Inc Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
PL2627673T3 (pl) * 2010-10-15 2018-01-31 Medimmune Ltd Terapie poprawiające funkcje płuc
KR101615420B1 (ko) 2010-12-16 2016-04-26 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
JP6715767B2 (ja) 2013-10-23 2020-07-01 ジェネンテック， インコーポレイテッド 好酸球性疾患の診断及び治療方法
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
EP3129497B1 (en) 2014-04-11 2021-09-08 Novartis AG Methods of selectively treating asthma using il-13 antagonists
EP3271723A1 (en) 2015-03-16 2018-01-24 F. Hoffmann-La Roche AG Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
US20190086392A1 (en) 2016-03-21 2019-03-21 Inserm (Institut National De La Sante Et De La Recherch Medicale) Methods for diagnosis and treatment of solar lentigo
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
WO2018135653A1 (ja) * 2017-01-23 2018-07-26 学校法人東洋大学 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出
CN109776677B (zh) * 2017-11-15 2023-11-03 尚华科创投资管理（江苏）有限公司 一种人源化抗il-13抗体及其制备方法和应用
CN107909501B (zh) * 2017-12-05 2020-12-01 创新先进技术有限公司 气味与行为的关联方法、气味社交方法及装置
KR20220098056A (ko) 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
JP2022525703A (ja) * 2019-03-20 2022-05-18 ジャベリン・オンコロジー・インコーポレイテッド 抗ａｄａｍ１２抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法
GB201919062D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
CN119684453B (zh) * 2024-12-19 2026-07-28 江苏荃信生物医药股份有限公司 一种人il-13抗体、elisa试剂盒及其检测方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501249A (ja) * 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド ワクチン
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
MX361174B (es) * 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
EP1976881A2 (en) 2008-10-08
ZA200805526B (en) 2009-10-28
CA2635972A1 (en) 2007-07-19
MA30156B1 (fr) 2009-01-02
AU2007204372A1 (en) 2007-07-19
GB0600488D0 (en) 2006-02-22
WO2007080174A2 (en) 2007-07-19
BRPI0706481A2 (pt) 2011-03-29
CR10161A (es) 2008-11-26
NO20082767L (no) 2008-10-06
TW200736274A (en) 2007-10-01
CN101370829A (zh) 2009-02-18
JP2009523154A (ja) 2009-06-18
KR20080113201A (ko) 2008-12-29
AR058955A1 (es) 2008-03-05
PE20081185A1 (es) 2008-10-07
WO2007080174A3 (en) 2007-12-06
IL192207A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
TW200736274A (en) Immunoglobulins
SG153878A1 (en) Chimeric and humanised monoclonal antibodies against inteleukin-13
WO2009052081A3 (en) Antibodies that bind il-4 and/or il-13 and their uses
CY1120874T1 (el) Συνθεση αντισωματος ιντερλευκινης-13
WO2009074634A3 (en) Polypeptides, antibody variable domains & antagonists
MX340696B (es) Anticuerpos anti-c5a y metodos para usar los anticuerpos.
WO2007045477A3 (en) Human antibodies against il-13 and therapeutic uses
WO2008097461A3 (en) Hepcidin and hepcidin antibodies
MX2009010765A (es) Anticuerpos anti-ige.
UA95478C2 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТ с-Kit
WO2007113172A3 (en) Antibodies against amyloid-beta peptide
WO2010021874A3 (en) Engineered anti-il-13 antibodies, compositions, methods and uses
NO20090224L (no) Anti-IL-6 monoklonale antistoffer og anvendelser derav
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
UA100377C2 (en) Antibodies against il-25
WO2010038155A3 (en) Antibodies against il-25
JP2014534239A5 (enExample)
WO2007003421A3 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
WO2007032804A3 (en) Novel uses for anti-ige therapy
TNSN08175A1 (en) Human antibodies against il-13 and therapeutic uses
WO2011080050A3 (en) Ccl21 binding molecules